intensively studied in clinical trials, showing not only hypoglycaemic effects but also influencing the comorbid metabolic components of the disease. These include the following: 1 -activin type II receptor modulators (bimagrumab), 2 -amylin or dual amylin-calcitonin receptor agonists (Pramlintide-amylin agonist), 3 -activator of adenosine monophosphate-activated protein kinase (AMPK) (A-769,662, thienopyridone), 4 -analogues of fibroblast growth factor 21 (pegbelfermin), 5 -fructose-1,6-bisphosphatase inhibitors (VK0612; MB07803), 6 -new GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide, lyxisenatide, semaglutide, efpeglenatide, glutazumab, ITCA-650), 7 -drugs affecting the activity of the sodium-glucose cotransporter (SGLT 1 and 2) (SGLT 1 -licogliflozin, sotagliflozin and LX2761; SGLT 2 -kanagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin and tofogliflozin), or 8 -imeglimin belonging to a new group of drugs, so-called glimin [1,2].

The space and time gait parameters with regard to the operated leg after hip arthroplasty indicate an improvement as compared with the baseline results; however, they do not reach the values found in healthy persons.

1. Radiological evaluation of treatment of periprosthetic femoral fractures after hip replacement surgery is one of the most difficult parts of patient status assessment in post-surgical patients. 2. The most common pathological radiographic findings were stem subsidence and the presence of osteolytic foci around Adams` arc. 3. The occurrence of a periprosthetic fracture did not significantly affect Beals and Tower scores.

is multidirectional therapeutic intervention, including both carbohydrate and lipid control and normalization of blood pressure. This strategy has been shown to be beneficial for diabetic patients and contributes to the reduction of total mortality, cardiovascular deaths, and the risk of microangiopathy [3,4].In recent years, several new drugs have been added to the treatment of T2DM, and others are being intensively studied in experimental or clinical trials, producing not only hypoglycaemic effects but also affecting metabolic comorbidities. These include the following: -type II activin receptor modulators (bimagrumab); -amylin or dual amylin-calcitonin receptor agonists (pramlintide -amylin agonist); -adenosine monophosphate-activated protein kinase (AMPK) activator (A-769,662, thienopyridone); -fibroblast growth factor 21 analogues (pegbelfermin), fructose-1,6-bisphosphatase inhibitors (VK0612; MB07803); -novel GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide, lyxisenatide, semaglutide, efpeglenatide, glutazumab, ITCA-650); -sodium-glucose co-transporters (SGLT-1 and -2) (SGLT-1 -licogliflozin, sotagliflozin and LX2761;

of rare diseases. Laurnberg et al. found that moderate to severe TO, according to the European Group on Graves' Orbitopathy (EUGOGO) classification, occurs with a prevalence of 16.1/million/year (women: 26.7; men: 5.5) in 4.9% of patients with GB, regardless of iodized salt supplementation [2]. A similar prevalence of moderate to severe TO has been confirmed by other authors [3,4].